The DGKL Working Group Guide Limits (Arbeitsgruppe Richtwerte) has published a proposal for deriving permissible analytical uncertainty limits related to biological variation data. Reference intervals were used to estimate biological variation. Biological variation data as basis for permissible uncertainty limits are generally accepted. These concepts usually apply a fixed factor leading to unrealistic stringent limits for quantities with a relatively small biological variation and to very permissive limits for quantities with relatively large biological variation. The working group has suggested a non-linear relation between biological variation and permissible uncertainty limits. The new approach has been exemplified with 84 quantities listed in the RiliBÄK (official German guidelines). The algorithms published allowed to derive permissible limits for all quantitative measurands in laboratory medicine. After its publication, three supplements appear necessary: 1. additional specifications of standard uncertainty, 2. a discussion on permissible limits for diagnosis and monitoring purposes, and 3. a discussion on circular reasoning in our approach. 
Introduction
The DGKL Working Group Guide Limits (Arbeitsgruppe Richtwerte) recently has published a proposal for deriving permissible uncertainty limits of biological variation data [1] . Reference intervals were used to estimate biological variation.
Biological variation data as the basis for permissible uncertainty limits are generally accepted. These concepts usually apply a fixed factor leading to unrealistic stringent limits for quantities with a relatively small biological variation (e.g. plasma sodium) and to very permissive limits for quantities with relatively large biological variation (e.g. plasma triglycerides). To avoid these drawbacks, the working group has suggested a non-linear relation between biological variation and permissible uncertainty limits [1] . This proposal led to a compromise between the biological variation model and the state-of-the-art concept.
The new approach has been published in detail and exemplified with 84 quantities listed in the RiliBÄK [2] . The algorithms published allow to derive permissible limits for all quantitative measurands in laboratory medicine. The concept was based on intermediate imprecision. After its publication, three supplements appear necessary: 1. additional specifications of standard uncertainty, 2. a discussion on permissible limits for diagnosis and monitoring purposes, and 3. a discussion on circular reasoning in our approach.
Additional specifications of standard uncertainty
Recently, we published a proposal for permissible uncertainty of quantitative measurements in laboratory medicine [1] . One component of the uncertainty can be inferred from the statistical variation of the results of a series of measurements [category A of the Guide to Measurement Uncertainty (GUM) concept] [3] . In terms of laboratory Table 1 : Various types of imprecision [3] [4] [5] .
ISO
Synonyms sometimes found in the literature
Repeatability
Immediate imprecision, within-run imprecision, short-term variability 2. Intermediate imprecision Within-laboratory imprecision, day-today imprecision 3. Reproducibility
Inter-laboratory imprecision medicine, it means the analytical imprecision and can be expressed by the experimental standard deviation. The term imprecision should be further specified.
Various international standard organizations [3-5] specified various types of standard uncertainty (imprecision) as summarized in Table 1 . The maximum time span of repeatability is 1 day. Intermediate imprecision covers measurements from several days. The position of the control material in one run should always be the same, preferably before unknown samples are determined. If several control samples are measured during 1 day, only the first result should be included for calculating the imprecision. Further details have been published by Thompson [6] .
The imprecision has several operational sources of uncertainty including, e.g. pipetting and temperature controlling, variations caused by operators (mainly calibration and maintenance) and manufacturer caused variations. The imprecision is expressed as standard deviation s or coefficient of variation CV. Evaluating s and CV, different lengths of series are used. However, both s and CV are estimations with confidence intervals decreasing with an increasing amount of repeats ( Figure 1 ). For n = 20 measurements, the additive effect of the confidence interval decreases to about 10% and the effect of additional repeats is small. The choice of n = 20 is a practical compromise followed by many medical laboratories worldwide.
Our proposal (1) was based on intermediate imprecision which is determined during one control cycle (e.g. 20 d × 1 = 20 days, one measurement per day), with one instrument/analytical system and the same control material as also claimed by CLSI [5] . Several operators may be involved. Variations caused by operators are included, but variations caused by the manufacturer (e.g. between reagent lot variation) are excluded. However, they are tolerated as long as the permissible expanded uncertainty is not exceeded. If calibration and maintenance actions are undertaken only occasionally, the control cycle can be extended to, e.g. a 3-month period to include these effects on s. The longer series result in smaller confidence intervals estimating s. However, for series lengths above 20 this effect is small (Figure 1 ).
The quantities to be assured should be close to the most appropriate reference limits. That means more than one control material should be applied. The German RiliBÄK requires at least two materials for each measurand [2] .
The imprecision as determined by control materials is an estimate of the actual imprecision designed for internal quality assurance purposes. It does not provide an estimate of the overall imprecision of the results received by the requesting physicians for materials taken from patients. For the latter purpose, the critical difference (also called reference change value) concept provides more meaningful information to the requester. Then, the uncertainty may be expressed as 1.64·(s A *+s I *)* [s A analytical standard deviation, s I intra-individual standard deviation].
If estimating imprecision, it is sometimes appropriate to eliminate suspect results which do not belong to the underlying distribution (outliers). Often, they are identified by subjective expertise. However, it is preferable to apply a statistical test. The literature contains a lot of more or less complicated outlier tests [8] . A simple and often used test was proposed by Youden [9] : elimination of all values outside mean±3s and recalculation of s (s = standard deviation). Probably, more reliable are the r-test [10, 11] or the Tukey Test [12] . 
Different permissible uncertainty limits for diagnostic and monitoring purposes?
Various concepts are suggested for uncertainty limits in laboratory medicine. Most proposals [13, 14] are based on biological variation (CV B ). If CV B is multiplied by a fixed factor common to all measurements, quantities with a relatively small CV B (e.g. plasma sodium) lead to a permissible analytical uncertainty (pU%) which is unrealistic low under the present technology, and quantities with a relatively large CV B have a pU% which is too permissive (e.g. plasma triglycerides). Therefore, Fraser [14] proposed three different factors and we proposed even five different factors [15] . If the analytical uncertainty obtained by the majority of medical laboratories is presented in relation to CV B , different factors lead to artificial jumps (as indicated by vertical black lines in Figure 2 ). An alternative is to use a curve with a continuous relation between CV B and pU% [1, 16] as demonstrated by blue diamonds in Figure 2 . So far, no consensus exists which biological variation should be applied to derive permissible limits for uncertainty. Different CV B concepts have been described: CV I means intra-individual variation, CV G inter-individual variation, CV C combined intra-and inter-individual variation, and CV E empirical biological variation (CV C and CV A , analytical variation).
Several authors proposed that CV I may be applied for monitoring purposes and CV G for diagnostic purposes [14, 17] . Although this idea can be scientifically justified, it does not appear realistic under routine conditions. Usually most medical laboratories serve diagnostic and monitoring purposes. In most cases, the laboratory does not know for which purpose a test is requested. Therefore, only the monitoring purpose should be chosen because it is most restrictive. Then, the adequate CV B would be CV I . The relation between CV I and pU% is also non-linear. In Figure 3 , the circles show a similar curved pattern than the rectangles in Figure 2 . The curved behavior is demonstrated by a local regression line in Figure 3 . Because the curves in Figures 2 and 3 are oriented on the technical Table B1a , column 3 [2] ). The black line is the local regression. reality (technical feasibility), the permissible U% obtained is similar. In this case, both CV B (CV I and CV E ) can be used to derive permissible uncertainty limits. We prefer to use the model based on CV E for several reasons [1] : it realizes a compromise between technical reality and biological variation, considers imprecision profiles, considers normal and skewed distributions, takes advantage of the fact that laboratories are obliged to use reference limits for all quantities determined either by establishing their own reference limits or to verify the transferability of reference limits chosen from outside sources. According to existing guidelines, all reference limits must be validated and periodically verified [4] .
Because permissible limits can be derived from any CV B concept and should be oriented on the technical reality, the purpose for its application (monitoring or diagnostic) should be of secondary concern in our model.
Discussion of circular reasoning
A frequently raised critical comment on our proposal is that the combination of CV A and CV C in CV E leads to a circular reasoning. Although this argument is correct, it can be neglected if the analytical variation is small in relation to the biological variation. This is the case for most measurands in clinical chemistry (Table 2) .
A relative large empirical biological variation was encountered for h-choriongonadotropine (hCG) and C-reactive protein with a CV E * = 51.4 and a pCV A = 7.15 [16] . Assuming a CV A = 7.0, and CV c = CV E * and CV C +pCV A = (54.4 2 +7.0 2 ) 0.5 = 51.9. The corresponding pCV A value of 7.19 means a negligible increase (+0.5%).
With plasma sodium (a quantity with a relatively small biological variation), the increase of CV E * is 7.6% due to the non-linear relation mentioned above (Table 2) . However, the pCV A derived of our model is equal to the permissible limit of the RiliBÄK [2] .
